secwatch.observer — SEC 8-K summary
======================================

Issuer:     Context Therapeutics Inc. (CNTX)
CIK:        0001842952
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001842952-25-000003
Event type: leadership
Sentiment:  positive
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Context Therapeutics appoints Andy Pasternak as Chairman; Richard Berman resigns from Board
--------------------------------------------------------------------------------

- Richard Berman resigned from Board effective Jan 12, 2025; not due to any disagreement with the Company.
- Andy Pasternak appointed Chairman effective Jan 13, 2025; term through 2027 annual meeting.
- Pasternak also appointed to Audit and Compensation Committees; Dr. Karen L. Smith named Compensation Committee Chair.
- Pasternak granted options to purchase 20,685 shares, vesting by June 13, 2025 or 2025 annual meeting; receives $55K annual cash retainer.
- Pasternak brings 25+ years pharma experience, including role in $28B Horizon-Amgen acquisition and Bain Healthcare leadership.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842952/000184295225000003/0001842952-25-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842952/000184295225000003/cntx-20250110.htm
  HTML page:      https://secwatch.observer/filing/0001842952-25-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer